Cleo Diagnostics Advances Ovarian Cancer Test Validation, Screening Program Clears Early Benchmarks
COV: $0.295 -1.67% · MC: $38M
Cleo Diagnostics received its first production batch of test kits and began analytical validation, while engaging a U.S. laboratory for pivotal clinical testing; it continues to target an FDA submission in the first half of 2027. Its screening program’s initial retrospective study exceeded the company’s stated performance benchmarks, an early research result that still requires confirmation in larger, intended-use populations. Cash stood at approximately A$4 million at quarter-end.

Comments